In-Vivo Acute Dermal Irritation Study Of Desonide-Curcumin Niosomal Gel: An Experimental Approachs

Authors

  • Rahul Waman
  • Ravikant Gupta
  • Sachin Kumar Jain
  • Sudha Vengurlekar

Keywords:

Curcumin, Desonide, Niosomal gel, Topical delivery, Dermal irritation, OECD 404 guideline, Draize scoring, Wistar rats, Skin safety evaluation

Abstract

Topical niosomal gels have gained considerable attention for enhancing localized drug delivery and reducing systemic side effects. Desonide, a corticosteroid, and curcumin, a natural anti-inflammatory compound, are both recognized for their therapeutic potential in treating skin inflammation. This study aimed to evaluate the dermal irritation potential of a Curcumin–Desonideniosomal gel in Wistar rats using OECD guideline 404. Thirty Wistar albino rats were randomly divided into five groups (n = 6 each): Group I (Normal Control), Group II (Positive Control with 0.8% formaldehyde), Group III (Placebo gel base), Group IV (Curcumin–Desonideniosomal gel), and Group V (Marketed Diclofenacniosomal gel). Skin reactions were observed and scored at 24, 48, and 72 hours post-application using the Draize scoring system for erythema, edema, and swelling. The results demonstrated no skin reactions in the normal control group, while the formaldehyde-treated group showed severe irritation with high scores across all parameters. The placebo group exhibited only very slight irritation at 24 hours that resolved by 48 hours. The Curcumin–Desonideniosomal gel group showed minimal erythema at 24 hours, with no edema or swelling, and no signs of irritation at 48 and 72 hours. The marketed niosomal gel also showed minimal erythema with no other adverse effects. These findings confirm that the Curcumin–Desonideniosomal gel is well-tolerated and non-irritant, supporting its potential as a safe and effective topical formulation for anti-inflammatory therapy.

Downloads

Download data is not yet available.

References

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008 Jul 24;454(7203):428–35. doi:10.1038/nature07201

Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008 Nov;26(11):1261–8. doi:10.1038/nbt.1504

Moghassemi S, Hadjizadeh A. Nano niosomes as nanoscale drug‐delivery systems: an illustrated review. J Control Release. 2014 Jul 10;185:22–36. doi:10.1016/j.jconrel.2014.04.015

Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997 Aug 26;154(2):123–40. doi:10.1016/S0378 5173(97)00135 X

Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Simpson EL, Maloney JM, et al. Safety and efficacy of desonide hydrogel 0.05% in children with atopic dermatitis. J Am AcadDermatol. 2007 Feb;56(2):222–8. doi:10.1016/j.jaad.2006.09.040

Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Mar;15(1):195–218. doi:10.1208/s12248 012 9437 4

Manca ML, Castangia I, Zaru M, Lai F, Valenti D, Sinico C, et al. Nanosystems for topical delivery of curcumin: a promising therapeutic strategy for inflammatory skin conditions. Colloids Surf B Biointerfaces. 2015 May;123:566–72. doi:10.1016/j.colsurfb.2014.11.031

Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009 Jan;41(1):40–59. doi:10.1016/j.biocel.2008.06.010

Baek JS, Cho CW. Niosomal formulations for delivery of dermatological drugs. Arch Pharm Res. 2020 Jan;43(1):1–12. doi:10.1007/s12272 019 01167 3

Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano based drug delivery systems for topical application: formulation and evaluation. Drug DevInd Pharm. 2017 Mar;43(3):381–92. doi:10.1080/03639045.2016.1248790

OECD. OECD Guidelines for the Testing of Chemicals. Test No. 404: Acute Dermal Irritation/Corrosion. OECD; 2015.

Waman RL, Loksh KR. Development and validation of reversed phase high performance liquid chromatography method for simultaneous estimation of desonide and curcumin in topical dosage form. Asian J Pharm. 2024;18(3):866. doi:10.22159/ajp.2024v18i3.73921

Kaur CD, Saraf S. Topical vesicular delivery system for anti inflammatory agents: design and development. Artif Cells Blood SubstitImmobilBiotechnol. 2011;39(3):130–8. doi:10.3109/10731199.2010.511294

Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug DevInd Pharm. 2003 Nov;29(9):1013–26. doi:10.1081/DDC 120024582

Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011 Sep;50(5):600–13.

Bhardwaj A, Kansal S, Kumar M, Rawat M, Chauhan NS, Sardana S. Development and evaluation of niosomal gel for topical delivery of benzoyl peroxide. Drug DelivLett. 2018 Mar;8(1):11–20.

ECD. OECD Guidelines for the Testing of Chemicals. Section 4. Test No. 404: Acute Dermal Irritation/Corrosion. OECD; 2015.

OECD. Guidance Document on Integrated Approaches to Testing and Assessment (IATA) for Skin Irritation/Corrosion. Series No. 203. OECD; 2014.

Draize JH. Appraisal of the safety of chemicals in foods, drugs and cosmetics. Assoc Food Drug Off U S. 1959;49:2–56.

Balls M, Goldberg AM, Fentem JH, Broadhead CL, Burch RL, Festing MF, et al. The three Rs: the way forward. Altern Lab Anim. 1995 Nov;23(6):838–66.

Parasuraman S. Toxicological screening. J PharmacolPharmacother. 2011 Apr;2(2):74–9. doi:10.4103/0976 500X.81834

Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009 Apr;8(2):173–9. doi:10.4314/tjpr.v8i2.46416

Benson HA. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005 Feb;2(1):23–33. doi:10.2174/1567201052773066

Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244–58. doi:10.1093/ilar.43.4.244

Pandey M, Choudhury H, Lim YM, Kok YY, Rajinikanth PS, Abdullah AH, et al. Skin irritation testing of transdermal patches containing anti inflammatory drugs using formalin as a positive control. Drug DelivTransl Res. 2020 Apr;10(2):324–33. doi:10.1007/s13346 019 00699 7

Jain A, Jain S, Jain RK, Mahajan SC. Development and evaluation of niosomal gel of diclofenac for transdermal delivery. J Drug DelivTher. 2014;4(2):74–80. doi:10.22270/jddt.v4i2.526

Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J PharmacolExpTher. 1944 Dec;82(3):377–90.

OECD. Test No. 404: Acute Dermal Irritation/Corrosion. OECD; 2015.

Gad SC. Animal Models in Toxicology. 3rd ed. Boca Raton: CRC Press; 2015. Chapter 14, Dermal Toxicity and Irritation Studies, p. 483–500.

Downloads

Published

2025-08-07

How to Cite

1.
Waman R, Gupta R, Kumar Jain S, Vengurlekar S. In-Vivo Acute Dermal Irritation Study Of Desonide-Curcumin Niosomal Gel: An Experimental Approachs. J Neonatal Surg [Internet]. 2025Aug.7 [cited 2025Sep.11];14(32S):7190-8. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/8784

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.